

Dag 5.1.2e

Wat heb je specifiek nodig voor dit onderdeel? En wat zijn de vergoedingen die er tegenover staan?

5.1.2e 5.1.2e van BDR is bij het RIVM eerder betrokken geweest bij HERA Incubator zaken (beleidsmatig), en kan wellicht helpen, maar zij kan niet haar agenda schoonvegen.

Andere optie is het Centrum Gezondheidsbescherming, maar een definitief antwoord daarover kan ik je niet geven vóór 17-3 (morgen).

Heb je meer info over HERA en wat de EC ermee wil?

5.1.2e 5.1.2e 5.1.2e

5.1.2e

WHO Collaborating Centre for the Family of International Classifications in the Netherlands
National Institute for Public Health and the Environment (RIVM)
Postal address 5.1.2e 1720 BA Bilthoven, The Netherlands || 5.1.2e
5.1.2e

Information on the WHO Family of International Classifications: <https://www.whoic.nl>
ICF, ICF-CY, ICD-10, ICPC-2 and CMSV online in Dutch: <https://class.whoic.nl/>

Van: 5.1.2e 5.1.2e <5.1.2e@nivel.nl>

Verzonden: dinsdag 16 maart 2021 12:35

Aan: 5.1.2e 5.1.2e 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e 5.1.2e 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e 5.1.2e
(5.1.2e @rcsi.ie <5.1.2e@rcsi.ie>; 5.1.2e 5.1.2e <5.1.2e@nivel.nl>; 5.1.2e 5.1.2e
<5.1.2e@nivel.nl>; 5.1.2e 5.1.2e <5.1.2e@nivel.nl>; 5.1.2e @gmail.com

Onderwerp: FW: Hera Incubator - follow up

Dear colleagues,

As part of the new contract I was asked by SANTE if we can support in the preparations of the HERA Incubator in response to the COVID-19 crisis. SANTE asked for 2 specific activities:

- a) to report on a public online consultation for the new HERA and
- b) to provide 1 or 2 discussion papers to support the impact assessment of the new HERA.

They asked if I can respond by tomorrow 17 March already. Especially for the impact assessment I have to ask 5.1.2e if he can check internally whether RIVM would be willing to see if it can have a leading role in that specific part as it's closest to RIVM's area of expertise (and perhaps RCSI as well?). As you can see below, SANTE asks for the delivery of a report on the economic impact of HERA; and a Quantitative analysis of environmental, health and social impacts of HERA.

You'll of course need more time than 17 March, but at least if you could indicate if there is a potential interest, then we can quickly set up a call with SANTE to get more clarification. *Note. We can also subcontract parts, so if you or colleagues know of another institute that can contribute to such an impact assessment, then we can also explore this. Internally I'll also ask a few colleagues if they are able to contribute.*

As for the online consultation: we can do that a bit more easily, but also there we need to define well what we can and cannot do, as analyzing open responses can be a lot of work, even if via text mining, as I tried to explain in an earlier note sent to SANTE.

Best wishes,

5.1.2e

Van: 5.1.2e [redacted] <[redacted]@ec.europa.eu>

Verzonden: dinsdag 16 maart 2021 10:57

Aan: 5.1.2e 5.1.2e

CC: 5.1.2e 5.1.2e

Onderwerp: Hera Incubator - follow up

Dear 5.1.2e

Firstly, many thanks for the input received on your possibilities to support on the HERA file.

1. Public Consultation questionnaire Report

We would like to confirm our interest in requesting NIVEL to support on the analysis of the public consultation feedback. As it stands, we would need to know by COB 17/03 if the below is agreeable for you:

- We aim to launch the questionnaire on 29/03. The Commission will draft and disseminate.
- The questionnaire will be open from 29/03 to the week of 03/05 (potentially if 6 weeks, the close of the PC should be on 10 May).
- The work on the report for the feedback of the consultation should take place starting week of 19 April and the final deliverable would need to be received by week of 31/05 at the latest (earlier would be beneficial – this would be the latest date possible)
- Please note that the questionnaire is aiming to have a maximum of 15 questions. The majority would be closed questions. There will be a multitude of stakeholders replying (citizens, organizations representing patients, consumers, civil society, active in public health and healthcare; healthcare professionals and healthcare providers; public authorities; businesses and their associations; researchers, academia and learned societies; international actors; and environmental organizations). We cannot estimate the exact amount of feedback which will be received.

2. Discussion papers

We would like to confirm our interest in requesting NIVEL to support the Impact Assessment via the delivery of a discussion(s)/analysis paper on: economic impact of HERA; Quantitative analysis of environmental, health and social impacts of HERA. These documents would serve as support reports for the Impact Assessment of HERA. As it stands, we would need to know by COB 17/03 if the below is agreeable for you:

- 2 papers – one on economic impact of HERA (including sustainability analysis – e.g. costs for setting up and maintaining the Authority) and the second on quantitative analysis of health/social/environmental impacts of HERA – specific questions to be defined.
- We would need to receive the final reports latest by 24/05.

Should the above be possible for you, please let us know by COB 17/03. If yes, we will then set up a ‘kick off’ meeting to start the work with you.

Kind regards,

5.1.2e on behalf of DG Sante

From: 5.1.2e 5.1.2e <5.1.2e@nivel.nl>

Sent: Friday, March 12, 2021 10:28 AM

To: 5.1.2e <5.1.2e@ec.europa.eu>

Cc: 5.1.2e 5.1.2e (SANTE) <5.1.2e@ec.europa.eu>

Subject: RE: Some questions

Dear 5.1.2e dear 5.1.2e

Apologies that my original response in writing and in the TC didn't yet address all topics below, as I only saw the e-mail with original questions yesterday evening. In the attached updated document I restructured our response to answer all questions, including whether we can analyse per stakeholder group (yes, easily) and have text mining expertise and tools (yes, to some extent).

A key question was whether we can assure to allocate sufficient human resources to deliver a report in two weeks. As we should be both flexible and reliable, the honest answer is that I can only partially provide such assurance in this stage, namely for the quantitative analysis, but not for the open question and position paper analysis.

The attached document provides a more detailed response, among others on the numbers of responses to expect (potentially including in other languages), the pros and cons of text mining and the likely need to provide a content and manual review which to some extent is unavailable. Very technical responses, e.g. including claims on vaccine effectiveness or side effects would then also require input from in colleagues from e.g. the Centre for Infectious Disease Control at our consortium partner RIVM, who cannot yet confirm their availability due to their own national response obligations.

Moreover, I anticipate that a planning of the consultation to be delivered around 10 May will be a risk in terms of time efforts from the core team, among others due to the High Level Conference on Mental Health and COVID-19 on that date, as well as potentially other obligations for the Europe's Beating Cancer Plan that should not jeopardize the HERA report. Should the closing deadline be later and should the run-through time be extended to e.g. 4 weeks before a final and publishable version of the report is delivered, then I believe it can be done in a more robust and reliable manner.

If the other contractor can provide more reassurance on that or any other element, then I would imagine them being the first choice. In that scenario we would also be happy to collaborate, e.g. conducting a specific component of the study. We would also be more than willing to support, advise, or help disseminate the consultation, if appropriate, and likely without budget requirements.

Do let me know if you have other information that may be relevant of if you would like us to support in any way possible and feasible.

Kind regards,

5.1.2e

Nivel | 5.1.2e | 5.1.2e@nivel.nl
Otterstraat 118 – 124 | 3513 CR Utrecht | 5.1.2e | 3500 BN Utrecht | The Netherlands
www.nivel.eu | www.nivel.nl/en | 5.1.2e



Van: 5.1.2e [mailto:5.1.2e@ec.europa.eu]

Verzonden: donderdag 11 maart 2021 17:05

Aan: 5.1.2e | 5.1.2e

CC: 5.1.2e | 5.1.2e

Onderwerp: Re: Some questions

Dear 5.1.2e

Could you also clarify the following:

Would NIVEL also be able to confirm that they have text mining tools/software as well? (These need to be used both for the analysis of open questions and free text upload in the public consultation as well as for the analysis of the position papers – apparently the tools they mention in the document are statistical tools).

Also, perhaps I missed it in the paper and the call with 5.1.2e but did he confirm if they can analyse per stakeholder group? If no, could we double-confirm this with him as well?

Many thanks in advance and kind regards,

5.1.2e

From: 5.1.2e (CHAFEA)
Sent: Thursday, 11 March 2021 10:20
To: 5.1.2e@nivel.nl
Cc: 5.1.2e | 5.1.2e (SANTE)
Subject: Some questions

Dear 5.1.2e

As per our phone call, see below. Could you send us the replies as soon as possible?

- Could you send us an example of a report prepared by Nivel on a public survey?
- Also, would you know how they are assessing the replies (e.g. by stakeholder group) and if they use a software? (They will need to summarize the replies to the public consultation questionnaire and the position papers.
- Also, it would be interesting to know if they have the infrastructure to deal with (more than) 1000 replies and filter out campaigns (sometimes we receive several similar/identical replies)?
- How many staff with relevant experience would be available to work on this project? (We need to be reassured that they will allocate sufficient human resources and provide the report very quickly (max 2 weeks?) once the public consultation is closed. It is not always so easy for companies to do so.)
- In terms of process, they have to send an offer mentioning all the details? How can we have a kick-off meeting in less than a week?

We look forward to hearing from you.

Kind regards,

5.1.2e

5.1.2e



European Commission

*Consumers, Health, Agriculture and Food Executive Agency
Health Unit*

5.1.2e

L-2920 Luxembourg

+352 5.1.2e

5.1.2e [@ec.europa.eu](mailto:5.1.2e@ec.europa.eu)

This message contains information that may be privileged or confidential and is the property of Nivel. It is intended exclusively for the person to whom it is addressed. If you are not the intended recipient you are not authorized to use this message or any part thereof. If you receive this message in error please notify the sender immediately and delete all copies of this message. Nivel rules out any and every liability resulting from any electronic transmission. No rights may be derived from the contents of this e-mail message. --

This message contains information that may be privileged or confidential and is the property of Nivel. It is intended exclusively for the person to whom it is addressed. If you are not the intended recipient you are not authorized to use this message or any part thereof. If you receive this message in error please notify the sender immediately and delete all copies of this message. Nivel rules out any and every liability resulting from any electronic transmission. No rights may be derived from the contents of this e-mail message. --

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability

This message contains information that may be privileged or confidential and is the property of Nivel. It is intended exclusively for the person to whom it is addressed. If you are not the intended recipient you are not authorized to use this message or any part thereof. If you receive this message in error please notify the sender immediately and delete all copies of this message. Nivel rules out any and every liability resulting from any electronic transmission. No rights may be derived from the contents of this e-mail message. --